Clinical and diagnostic significance of preoperative computed tomography findings of ascites in patients with advanced gastric cancer

Yajima, Kazuhito; Kanda, Tatsuo; Ohashi, Manabu; Wakai, Toshifumi; Nakagawa, Satoru; Sasamoto, Ryuta; Hatakeyama, Katsuyoshi

doi:10.1016/j.amjsurg.2006.05.007

Cited by 50 publications

(36 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In general, the clinical diagnosis of carcinomatosis is made based on radiological Wndings, such as ascites or peritoneal nodules (Yajima et al 2006). However, it is sometimes diYcult to diagnose peritoneal metastasis using only conventional techniques.…”

Section: Discussionmentioning

confidence: 99%

“…The diagnosis of carcinomatosis was made based on clinical and radiological Wndings. The radiological parameters of carcinomatosis from computed tomography were as follows: (1) ascites, (2) thickening of bowel walls, (3) increased density of peritoneal fat, (4) the presence of peritoneal seeding nodules, or (5) hydronephrosis from ureteral obstruction (Yajima et al 2006). Patients were excluded from the study if they had any other cancers, or other benign diseases with ascites, such as tuberculous peritonitis, liver cirrhosis, or end stage renal disease.…”

Section: Patientsmentioning

confidence: 99%

See 1 more Smart Citation

The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites

Jung

Jeung

Lee

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Patientsmentioning

confidence: 99%

The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites

Jung

Jeung

Lee

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Chang et al [38] noted that when the estimated CT-defined ascitic volume was ‡ 50 mL, peritoneal carcinomatosis was identified in 75%-100% of patients. Yajima et al [39] reported that positive ascites on CT predicted the presence of peritoneal metastasis with 51% sensitivity and 97% specificity. Therefore, when ascites is detected on CT images, we should search for seeded nodules in the peritoneal cavity.…”

Section: Stagingmentioning

confidence: 98%

Gastric cancer: Imaging and staging with MDCT based on the 7th AJCC guidelines

et al. 2011

View full text Add to dashboard Cite

Gastric cancer is a common deadly cancer worldwide. The tumor-node-metastasis (TNM) staging system is one of the most commonly used staging systems, and is accepted and maintained by the International Union against Cancer (UICC) and the American Joint Committee on Cancer (AJCC). The TNM system is well known to effectively predict the prognosis of gastric cancer patients. The latest revision of TNM staging was presented in the 7th edition of the AJCC in 2009. Multi-detector row CT (MDCT) is a powerful test for non-invasive evaluation and can assess metastatic and locoregional staging simultaneously. Current MDCT with isotropic imaging and 3D images has increased the accuracy of T and N staging in patients with gastric cancer. Multi-planar reformatted images permit the radiologist to select the optimal imaging plane to accurately evaluate tumor invasion depth of the gastric wall and perigastric infiltration to identify a fat plane between a tumor and adjacent organs, to avoid partial volume averaging effects, and to differentiate lymph nodes from small perigastric vessels. Thus, MDCT provides a useful all-in-one diagnostic method for the pre-operative evaluation of patients with known, or strongly suspected, gastric cancer according to the 7th AJCC TNM staging system.

show abstract

“…We collected the body fluids of 36 patients, who were clinically diagnosed with metastatic stage IV breast carcinoma with malignant ascites or pleural effusion ( (15). When the body fluid was detected for the first time in each patient, it was collected through paracentesis or thoracentesis.…”

Section: Patientsmentioning

confidence: 99%

Body fluid MMP-2 as a putative biomarker in metastatic breast cancer

Noh

Jung

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

Abstract. In the present study, we investigated the role of matrix metalloproteinase (MMP)-2 and -9 as novel biomarkers in the body fluid of patients with metastatic breast cancer. We measured the expression of MMPs in 37 samples of body fluid (10 peritoneal and 27 pleural fluids) from metastatic breast cancer patients between 2000 and 2009. Zymography and ELISA assays were used to determine the cut-off level and to quantify MMP expression from a positive control, HT-1080 conditioned media. MMP expression in patient samples was measured with ELISA and compared with other clinical parameters. Ascitic carcinoembryonic antigen (CEA) and pleural CEA were measured in patient samples with a chemiluminescent enzyme immunoassay. Body fluid cytology had a positivity of 45% (9/20) for pleural fluid and 28.6% (2/7) for ascites. However, MMP-2 had a positivity of 85.2% (23/27) in 27 pleural fluid samples and 100% (10/10) in ascitic fluid with cut-off levels of 8.6 and 0.14 ng/ml for MMP-2 and -9, respectively. When body fluid CEA and MMP-2 were combined, the positivity improved to 96% in pleural fluid and 100% in ascites. MMP-2 expression in body fluid did not show any significant differences, but MMP-9 expression was lower in ascites than in pleural fluids (p<0.005). Our results suggest that MMP-2 expression in body fluid be used as an additive diagnostic marker for metastatic breast cancer patients.

show abstract

Clinical and diagnostic significance of preoperative computed tomography findings of ascites in patients with advanced gastric cancer

Cited by 50 publications

References 12 publications

The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites

The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites

Gastric cancer: Imaging and staging with MDCT based on the 7th AJCC guidelines

Body fluid MMP-2 as a putative biomarker in metastatic breast cancer

Contact Info

Product

Resources

About